A Randomized Phase II/III Study of Docetaxel and Ramucirumab with or Without Cemiplimab (REGN2810) for Participants Previously Treated with Platinum-based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
- Sponsor:
- SWOG
- Sponsor Study ID:
- S1800E
- CTO #:
- 104263
- NCT Number:
- NCT06616584
- Phase:
- II/III
- Protocol Type:
- Treatment
- Age Group:
- Adults
- Disease Sites:
- Lung
- Study Objectives:
- The primary objective of the study is to compare overall survival (OS) between participants randomized to docetaxel and ramucirumab with or without cemiplimab (REGN2810) who have acquired resistance to platinum-based chemotherapy and immunotherapy for Stage IV or recurrent Non-Small Cell Lung Cancer (NSCLC).
- eConsent:
- Not available
- Study Documents:
-
Open Study Documents
(MUSC NetID required for document access)
For more information about this trial please contact the study team:
-
Medical University of South Carolina
- Affiliate Principal Investigator, Lupak, Oleksandra, at oll203@musc.edu .
- Principal Investigator, Rangel, Christopher, at rangelc@musc.edu .
- Study Coordinator, Morgan, Shelby, at morshelb@musc.edu .
-
Ralph H. Johnson VAMC
- Study Coordinator, Jeter, Kathy, at katherine.jeter2@va.gov .
Trial opened at the following institutions:
Ralph H. Johnson VAMC, Medical University of South Carolina